Skip to main content

Market Overview

Pfizer In Talks With Israel For New COVID-19 Vaccine Supply Deal: Reuters

Share:
Pfizer In Talks With Israel For New COVID-19 Vaccine Supply Deal: Reuters
  • Pfizer Inc (NYSE: PFE) is reportedly working on a new COVID-19 vaccine supply deal to Israel after an initial agreement announced in late 2020 has ended.
  • “The company is currently working with the Israeli government to update the agreement, to supply additional vaccines to the country. While this work continues, shipments may be adjusted,” Pfizer said.
  • Pfizer and its partner BioNTech SE (NASDAQ: BNTX) agreed in November to supply Israel with an undisclosed number of COVID-19 vaccines. Israel’s Finance Ministry has said it paid roughly 2.6 billion shekels ($785 million).
  • According to Reuters, Israel’s government seeks to secure 36 million more Pfizer/BioNTech doses for use as booster shots for children once they are eligible. It was set to approve a supply of around 3.5 billion shekels.
  • But the cabinet called off in a squabble between Prime Minister Benjamin Netanyahu and his defense minister, Benny Gantz, who heads a rival party over judicial appointments.
  • As per Jerusalem Post, a shipment of 700,000 doses was set to arrive on Sunday but was halted after the state failed to approve the transfer of payment for the previous 2.5 million doses Pfizer/BioNTech had supplied.
  • Price Action: PFE shares are down 0.12% at $36.25, while BNTX shares 0.47% at $114.4 during market trading hours on the last check Monday.
 

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: COVID-19 Vaccine israelBiotech Government News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com